The mesenchymal tumor microenvironment: A drug-resistant niche

Cell Adhesion and Migration

Volumn 6, Issue 3, 2012, Pages 285-296

  Cukierman, Edna ^a   Bassi, Daniel E ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Extracellular matrix; Matrix induced drug resistance; Mesenchymal stroma; Stromal induced drug resistance; Tumor microenvironment; Tumor associated or carcinoma associated fibroblasts; Tumor stromal interactions

Indexed keywords

BETA1 INTEGRIN; CELL ADHESION MOLECULE; CERIVASTATIN; CHEMOKINE RECEPTOR CXCR4; ETARACIZUMAB; FLUINDOSTATIN; MEVINOLIN; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; NANOPARTICLE; NATALIZUMAB; PACLITAXEL; PLERIXAFOR; SARIDEGIB; SILTUXIMAB; SIMVASTATIN; STROMAL CELL DERIVED FACTOR 1;

APOPTOSIS; BONE MARROW; CANCER CELL; CELL ADHESION; CELL MIGRATION; DIAGNOSTIC TEST; DNA SEQUENCE; DRUG RESISTANCE; ECOLOGICAL NICHE; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; MESENCHYMAL STROMA CELL; MESENCHYMOMA; MUTATION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE;

EID: 84863110695     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.20210     Document Type: Review

References (161)

1. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53:615-27; PMID:11818492; http://dx.doi.org/10.1146/annurev.med.53.082901.103929
2. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010; 46:308-16; PMID:20717753; http://dx.doi.org/10.1007/s12033-010-9321-2
3. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 2010; 10:871-7; PMID:21048784; http://dx.doi.org/10.1038/nrc2933
4. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008; 111:5477-85; PMID:18388178; http://dx.doi.org/10.1182/blood-2008-01-132837
5. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7:834-46; PMID:17957189; http://dx.doi.org/10. 1038/nrc2256
6. Royer C, Lu X. Epithelial cell polarity: a major gatekeeper against cancer?. [quest]. Cell Death Differ 2011; 18:1470-7; PMID:21617693; http://dx.doi.org/10.1038/cdd.2011.60
7. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi.org/10.1016/j.cell.2008.03. 027
8. Slatkin M. Epigenetic inheritance and the missing heritability problem. Genetics 2009; 182:845-50; PMID:19416939; http://dx.doi.org/10.1534/genetics. 109.102798
9. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27-36; PMID:19752007; http://dx.doi.org/10.1093/carcin/bgp220
10. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006; 12:4147-53; PMID:16857785; http://dx.doi.org/10.1158/1078-0432.CCR-06-0038
11. Basu D, Nguyen TT, Montone KT, Zhang G, Wang LP, Diehl JA, et al. Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity. Oncogene 2010; 29:4170-82; PMID:20498638; http://dx.doi.org/10.1038/onc.2010.170
12. Coldman AJ, Goldie JH. A stochastic model for the origin and treatment of tumors containing drugresistant cells. Bull Math Biol 1986; 48:279-92; PMID:3828558
13. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984; 44:3643-53; PMID:6744284
14. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 1991; 51:995-1002; PMID:1988143
15. Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res 2003; 63:7900-6; PMID:14633719
16. Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990; 247:1457-61; PMID: 2108497; http://dx.doi.org/10.1126/ science.2108497
17. Borovski T, De Sousa E Melo F, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res 2011; 71:634-9; PMID:21266356; http://dx.doi.org/10.1158/0008-5472.CAN-10-3220
18. Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol 2010; 80:762-70; PMID:20417189; http://dx.doi.org/10.1016/j.bcp.2010.04.020
19. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8:878-84; PMID:11895922
20. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9: 665-74; PMID:19693095; http://dx.doi.org/10.1038/nrc2714
21. Lohi J, Leivo I, Oivula J, Lehto VP, Virtanen I. Extracellular matrix in renal cell carcinomas. Histol Histopathol 1998; 13:785-96; PMID:9690136
22. Capo-Chichi CD, Smith ER, Yang DH, Roland IH, Vanderveer L, Cohen C, et al. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer 2002; 95:1802-15; PMID:12365030; http://dx.doi.org/10.1002/cncr.10870
23. Goetz JG, Minguet S, Navarro-Lérida I, Lazcano JJ, Samaniego R, Calvo E, et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011; 146:148-63; PMID:21729786; http://dx.doi.org/10.1016/j.cell.2011.05.040
24. Beacham DA, Cukierman E. Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol 2005; 15:329-41; PMID:15970443; http://dx.doi.org/10.1016/j.semcancer.2005.05.003
25. Hazlehurst LA, Landowski TH, Dalton WS. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003; 22:7396-402; PMID:14576847; http://dx.doi.org/10.1038/sj.onc.1206943
26. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003; 17:1175-82; PMID:12764386; http://dx.doi.org/10.1038/sj.leu.2402924
27. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008; 14:2519-26; PMID:18451212; http://dx.doi.org/10.1158/1078-0432.CCR-07-2223
28. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121:335-48; PMID:15882617; http://dx.doi.org/10.1016/j.cell.2005.02.034
29. Zhao C, Lu X, Bu X, Zhang N, Wang W. Involvement of tumor necrosis factor-alpha in the upregulation of CXCR4 expression in gastric cancer induced by Helicobacter pylori. BMC Cancer 2010; 10:419; PMID:20699000; http://dx.doi.org/10.1186/1471-2407-10-419
30. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203:2201-13; PMID:16940167; http://dx.doi.org/10.1084/jem.20052144
31. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 2006; 20:1915-24; PMID:16900209; http://dx.doi.org/10.1038/sj.leu.2404357
32. Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 2007; 21:1249-57; PMID:17410186; http://dx.doi.org/10.1038/sj.leu.2404684
33. Spiegel A, Kollet O, Peled A, Abel L, Nagler A, Bielorai B, et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood 2004; 103: 2900-7; PMID:15070661; http://dx.doi.org/10.1182/blood-2003-06-1891
34. Maréchal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 2009; 100: 1444-51; PMID:19352387; http://dx.doi.org/10.1038/sj.bjc.6605020
35. Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H, et al. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer 2009; 124:853-61; PMID:19035451; http://dx.doi.org/10.1002/ijc.24040
36. Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 2010; 103:1671-9; PMID: 21045835; http://dx.doi.org/10.1038/sj.bjc.6605968
37. Hattermann K, Held-Feindt J, Lucius R, Müerköster SS, Penfold ME, Schall TJ, et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 2010; 70:3299-308; PMID:20388803; http://dx.doi.org/10.1158/0008-5472.CAN-09-3642
38. Margolin DA, Silinsky J, Grimes C, Spencer N, Aycock M, Green H, et al. Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1a/CXCR4 paracrine signaling. Neoplasia 2011; 13:874-86; PMID:21969820
39. Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95:2630-6; PMID:10753844
40. Bisping G, Leo R, Wenning D, Dankbar B, Padró T, Kropff M, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003; 101:2775-83; PMID: 12517814; http://dx.doi.org/10. 1182/blood-2002-09-2907
41. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15:1950-61; PMID: 11753617; http://dx.doi.org/10.1038/sj.leu.2402295
42. de la Fuente MT, Casanova B, Moyano JV, Garcia-Gila M, Sanz L, Garcia-Marco J, et al. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 2002; 71:495-502; PMID:11867687
43. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003; 9:1158-65; PMID:12897778; http://dx.doi.org/10.1038/nm909
44. Taylor ST, Hickman JA, Dive C. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst 2000; 92:18-23; PMID:10620629; http://dx.doi.org/10.1093/jnci/ 92.1.18
45. Weekes CD, Kuszynski CA, Sharp JG. VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells. Leuk Lymphoma 2001; 40:631-45; PMID:11426535; http://dx.doi.org/10.3109/10428190109097661
46. Hodkinson PS, Elliott T, Wong WS, Rintoul RC, Mackinnon AC, Haslett C, et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ 2006; 13:1776-88; PMID:16410797; http://dx.doi.org/10.1038/sj.cdd.4401849
47. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001; 20:4995-5004; PMID:11526484; http://dx.doi.org/10.1038/sj.onc.1204554
48. Hazlehurst LA, Argilagos RF, Dalton WS. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br J Haematol 2007; 136:269-75; PMID:17233818; http://dx.doi.org/10.1111/j.1365-2141.2006.06435.x
49. Li L, Milner LA, Deng Y, Iwata M, Banta A, Graf L, et al. The human homolog of rat Jagged1 expressed by marrow stroma inhibits differentiation of 32D cells through interaction with Notch1. Immunity 1998; 8:43-55; PMID:9462510; http://dx.doi.org/10.1016/S1074-7613(00)80457-4
50. Walker L, Lynch M, Silverman S, Fraser J, Boulter J, Weinmaster G, et al. The Notch/Jagged pathway inhibits proliferation of human hematopoietic progenitors in vitro. Stem Cells 1999; 17:162-71; PMID: 10342559; http://dx.doi.org/10.1002/stem.170162
51. Ristorcelli E, Lombardo D. Targeting Notch signaling in pancreatic cancer. Expert Opin Ther Targets 2010; 14:541-52; PMID:20392166; http://dx.doi.org/10.1517/14728221003769895
52. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 2011; 30:4874-86; PMID:21625222; http://dx.doi.org/10.1038/onc.2011.195
53. Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin a-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol 2011; 155:53-64; PMID:21749361; http://dx.doi.org/10. 1111/j.1365-2141.2011.08794.x
54. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002; 2:91-100; PMID:12635172; http://dx.doi.org/10.1038/nrc727
55. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009; 69:4001-9; PMID:19383907; http://dx.doi.org/10.1158/0008-5472.CAN-08-4173
56. Taylor ST, Hickman JA, Dive C. Survival signals within the tumour microenvironment suppress drug-induced apoptosis: lessons learned from B lymphomas. Endocr Relat Cancer 1999; 6:21-3; PMID:10732782; http://dx.doi.org/ 10.1677/erc.0.0060021
57. Mimeault M, Hauke R, Batra SK. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 2008; 83:673-91; PMID: 17786164; http://dx.doi.org/10.1038/sj.clpt.6100296
58. Durand RE, Sutherland RM. Effects of intercellular contact on repair of radiation damage. Exp Cell Res 1972; 71:75-80; PMID:5063574; http://dx.doi.org/10.1016/0014-4827(72)90265-0
59. Gupta V, Bassi DE, Simons JD, Devarajan K, Al-Saleem T, Uzzo RG, et al. Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS One 2011; 6:e21494; PMID: 21738681; http://dx.doi.org/10. 1371/journal.pone.0021494
60. Quiros RM, Valianou M, Kwon Y, Brown KM, Godwin AK, Cukierman E. Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner. Gynecol Oncol 2008; 110:99-109; PMID:18448156; http://dx.doi.org/10.1016/j.ygyno.2008.03.006
61. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007; 130:601-10; PMID:17719539; http://dx.doi.org/10.1016/j.cell. 2007.08.006
62. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-67; PMID:10029595
63. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010; 14:45-55; PMID:20001209; http://dx.doi.org/10.1517/14728220903431069
64. Serebriiskii I, Castelló-Cros R, Lamb A, Golemis EA, Cukierman E. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol 2008; 27:573-85; PMID:18411046; http://dx.doi.org/10.1016/j.matbio.2008.02.008
65. Eberle KE, Sansing HA, Szaniszlo P, Resto VA, Berrier AL. Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB. PLoS One 2011; 6: e21496; PMID:21720550; http://dx.doi.org/10.1371/journal.pone. 0021496
66. Nam JM, Onodera Y, Bissell MJ, Park CC. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res 2010; 70:5238-48; PMID:20516121; http://dx.doi.org/10.1158/0008-5472.CAN-09-2319
67. Sebens Müerköster S, Kötteritzsch J, Geismann C, Gast D, Kruse ML, Altevogt P, et al. alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma. Int J Oncol 2009; 34:243-53; PMID:19082495
68. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19:4319-27; PMID:10980607; http://dx.doi.org/10.1038/sj.onc.1203782
69. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-61; PMID:19460966; http://dx.doi.org/10.1126/science.1171362
70. Castelló-Cros R, Cukierman E. Stromagenesis during tumorigenesis: characterization of tumor-associated fibroblasts and stroma-derived 3D matrices. Methods Mol Biol 2009; 522:275-305; PMID:19247611; http://dx.doi.org/10.1007/ 978-1-59745-413-1-19
71. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci 2010; 123:4195-200; PMID:21123617; http://dx.doi.org/10.1242/jcs.023820
72. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139:891-906; PMID:19931152; http://dx.doi.org/10.1016/j.cell.2009.10.027
73. Amatangelo MD, Bassi DE, Klein-Szanto AJ, Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am J Pathol 2005; 167:475-88; PMID:16049333; http://dx.doi.org/10.1016/S0002-9440(10)62991-4
74. Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009; 15:6630-8; PMID:19843665; http://dx.doi.org/10.1158/1078-0432.CCR-09-1001
75. Flach EH, Rebecca VW, Herlyn M, Smalley KS, Anderson AR. Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol Pharm 2011; 8:2039-49; PMID:22067046; http://dx.doi.org/10.1021/mp200421k
76. Atkinson JC, Rühl M, Becker J, Ackermann R, Schuppan D. Collagen VI regulates normal and transformed mesenchymal cell proliferation in vitro. Exp Cell Res 1996; 228:283-91; PMID:8912722; http://dx.doi.org/10.1006/excr.1996. 0328
77. Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BY, Gasson JC, et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res 2000; 60:6744-9; PMID:11118061
78. Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003; 3:377-86; PMID:12726863; http://dx.doi.org/10.1016/S1535-6108(03) 00058-8
79. Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011; 11:245; PMID:21668992; http://dx.doi.org/10.1186/1471-2407-11-245
80. Castelló-Cros R, Khan DR, Simons J, Valianou M, Cukierman E. Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer 2009; 9:94; PMID:19323811; http://dx.doi.org/10.1186/1471-2407-9-94
81. Kwon Y, Cukierman E, Godwin AK. Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/ invasion. PLoS One 2011; 6:e18872; PMID:21526198; http://dx.doi.org/10.1371/journal.pone.0018872
82. Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A, et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 2008; 6:1155-61; PMID:18639493; http://dx.doi.org/10.1016/j.cgh.2008.05.006
83. Klein CA. Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev 2011; 21:42-9; PMID:21145726; http://dx.doi.org/10.1016/j.gde.2010.10.011
84. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009; 69:1009-15; PMID:19155309; http://dx.doi.org/10. 1158/0008-5472.CAN-08-2419
85. Sansing HA, Sarkeshik A, Yates JR, Patel V, Gutkind JS, Yamada KM, et al. Integrin aβ1, avβ, a6β effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance. Biochem Biophys Res Commun 2011; 406:171-6; PMID:21291860; http://dx.doi.org/10.1016/j.bbrc.2011.01.109
86. Gong J, Ko TC, Brattain MG. Disruption of fibronectin binding to the alpha 5 beta 1 integrin stimulates the expression of cyclin-dependent kinases and DNA synthesis through activation of extracellular signal-regulated kinase. J Biol Chem 1998; 273:1662-9; PMID:9430710; http://dx.doi.org/10.1074/jbc.273.3. 1662
87. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269:682-5; PMID:7624798; http://dx.doi.org/10.1126/science.7624798
88. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, et al. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 1999; 274: 13886-93; PMID:10318797; http://dx.doi.org/10.1074/jbc.274.20.13886
89. Nakayama K, Nagahama H, Minamishima YA, Matsumoto M, Nakamichi I, Kitagawa K, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 2000; 19:2069-81; PMID: 10790373; http://dx.doi.org/10.1093/emboj/19.9.2069
90. Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, et al. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 2007; 110:1631-8; PMID:17502456; http://dx.doi.org/10.1182/blood-2006-11-060350
91. Henriet P, Zhong ZD, Brooks PC, Weinberg KI, DeClerck YA. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci U S A 2000; 97:10026-31; PMID:10944199; http://dx.doi.org/10.1073/pnas.170290997
92. Estrugo D, Fischer A, Hess F, Scherthan H, Belka C, Cordes N. Ligand bound beta1 integrins inhibit procaspase-8 for mediating cell adhesion-mediated drug and radiation resistance in human leukemia cells. PLoS One 2007; 2:e269; PMID:17342203; http://dx.doi.org/10.1371/journal.pone.0000269
93. Shakibaei M, John T, Seifarth C, Mobasheri A. Resveratrol inhibits IL-1 beta-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro. Ann N Y Acad Sci 2007; 1095:554-63; PMID:17404069; http://dx.doi.org/10.1196/annals.1397.060
94. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5:662-8; PMID:10371505; http://dx.doi.org/10.1038/9511
95. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129:1261-74; PMID:17604717; http://dx.doi.org/10.1016/j.cell.2007.06.009
96. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14:381-95; PMID:11882383; http://dx.doi.org/10.1016/S0898-6568(01)00271-6
97. Shain KH, Landowski TH, Dalton WS. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002; 168:2544-53; PMID:11859150
98. Gilbert LA, Hemann MT. Chemotherapeutic resistance: surviving stressful situations. Cancer Res 2011; 71:5062-6; PMID:21771909; http://dx.doi.org/10. 1158/0008-5472.CAN-11-0277
99. Joyce JA. Therapeutic targeting of the tumor micro-environment. Cancer Cell 2005; 7:513-20; PMID:15950901; http://dx.doi.org/10.1016/j.ccr.2005.05.024
100. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007; 25:1637-8; PMID:17470853; http://dx.doi.org/10.1200/JCO.2006.09.8376
101. Preusser M, de Ribaupierre S, Wöhrer A, Erridge SC, Hegi M, Weller M, et al. Current concepts and management of glioblastoma. Ann Neurol 2011; 70:9-21; PMID:21786296; http://dx.doi.org/10.1002/ana.22425
102. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010; 9:804-20; PMID:20885411; http://dx.doi.org/10.1038/nrd3266
103. Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002; 62:5019-26; PMID:12208756
104. Bisping G, Wenning D, Kropff M, Gustavus D, Müller-Tidow C, Stelljes M, et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Clin Cancer Res 2009; 15:520-31; PMID:19147757; http://dx.doi.org/10.1158/1078-0432.CCR-08-1612
105. Sherman MH, Downes M, Evans RM. Nuclear receptors as modulators of the tumor microenvironment. Cancer Prev Res (Phila) 2012; 5:3-10; PMID:22135047; http://dx.doi.org/10.1158/1940-6207. CAPR-11-0528
106. Fu Y, Fang Z, Liang Y, Zhu X, Prins P, Li Z, et al. Overexpression of integrin beta1 inhibits proliferation of hepatocellular carcinoma cell SMMC-7721 through preventing Skp2-dependent degradation of p27 via PI3K pathway. J Cell Biochem 2007; 102:704-18; PMID:17407140; http://dx.doi.org/10.1002/jcb.21323
107. Piperdi B, Ling YH, Liebes L, Muggia F, Perez-Soler R. Bortezomib: understanding the mechanism of action. Mol Cancer Ther 2011; 10:2029-30; PMID:22072812; http://dx.doi.org/10.1158/1535-7163. MCT-11-0745
108. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906-17; PMID:18753647; http://dx.doi.org/10.1056/NEJMoa0801479
109. Bonaca MP, Steg PG, Feldman LJ, Canales JF, Ferguson JJ, Wallentin L, et al. Antithrombotics in acute coronary syndromes. J Am Coll Cardiol 2009; 54:969-84; PMID:19729112; http://dx.doi.org/10.1016/j.jacc.2009.03.083
110. Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 2010; 67:923-30; PMID:20697042; http://dx.doi.org/10.1001/archneurol.2010.161
111. Bagley RG, Hudson LG, Stack MS. Integrins and Cancer. In: Teicher BA, ed. The Tumor Microenvironment: Springer New York, 2010:509-29.
112. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10:9-22; PMID:20029421; http://dx.doi.org/10.1038/nrc2748
113. Yamada KM, Pankov R, Cukierman E. Dimensions and dynamics in integrin function. Braz J Med Biol Res 2003; 36:959-66; PMID:12886449; http://dx.doi.org/10.1590/S0100-879X2003000800001
114. Larsen M, Artym VV, Green JA, Yamada KM. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 2006; 18:463-71; PMID:16919434; http://dx.doi.org/10. 1016/j.ceb.2006.08.009
115. Barkan D, Chambers AF. β1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res 2011; 17:7219-23; PMID:21900388; http://dx.doi.org/10.1158/1078-0432. CCR-11-0642
116. Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM. Integrins and cancer. [Williston Park]. Oncology (Williston Park) 2007; 21(Suppl 3):13-20; PMID:17927026
117. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004; 90:561-5; PMID:14760364; http://dx.doi.org/10.1038/ sj.bjc.6601576
118. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008; 8:604-17; PMID:18497750; http://dx.doi.org/10.1038/nrc2353
119. Katz BZ. Adhesion molecules - The lifelines of multiple myeloma cells. Semin Cancer Biol 2010; 20:186-95; PMID:20416379; http://dx.doi.org/10.1016/j. semcancer.2010.04.003
120. Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 2006; 94:1621-6; PMID:16705310
121. Hersey P, Sosman J, O'Day S, Richards J, Bedikian A, Gonzalez R, et al. Etaracizumab Melanoma Study Group. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010; 116:1526-34; PMID:20108344; http://dx.doi.org/10.1002/cncr.24821
122. Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 2008; 26:35-43; PMID:17876527; http://dx.doi.org/10.1007/s10637-007-9077-0
123. Stokes JB, Adair SJ, Slack-Davis JK, Walters DM, Tilghman RW, Hershey ED, et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther 2011; 10:2135-45; PMID:21903606; http://dx.doi.org/10.1158/1535-7163.MCT-11-0261
124. Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res 2008; 68:4398-405; PMID:18519702; http://dx.doi.org/10.1158/0008- 5472.CAN-07-6390
125. Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, et al. Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 2010; 70:2256-63; PMID:20197472; http://dx.doi.org/10.1158/0008-5472.CAN-09-4032
126. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010; 122:35-43; PMID:19701706; http://dx.doi.org/10.1007/s10549-009-0502-2
127. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through down-regulation of VLA-4 expression in multiple myeloma. Oncogene 2009; 28:231-42; PMID:18850009; http://dx.doi.org/10.1038/onc.2008.385
128. Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, et al. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol 2011; 155:438-48; PMID:21923653; http://dx.doi.org/10.1111/j.1365-2141. 2011.08864.x
129. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007; 356:2622-9; PMID:17582072; http://dx.doi.org/10.1056/NEJMct071462
130. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136:1182-97; PMID:19249397; http://dx.doi.org/10.1053/j.gastro.2009.02.001
131. Vishnu P, Roy V. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer. Womens Health (Lond Engl) 2010; 6:495-506; PMID:20597612; http://dx.doi.org/10.2217/whe.10.42
132. Montero AJ, Adams B, Diaz-Montero CM, Glück S. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol 2011; 4:329-34; PMID:22114779; http://dx.doi.org/10.1586/ecp.11.7
133. Shepard DR, Dreicer R, Garcia J, Elson P, Magi-Galluzzi C, Raghavan D, et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol 2009; 181:1672-7, discussion 1677; PMID:19230915; http://dx.doi.org/10.1016/j.juro.2008.11.121
134. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29:4548-54; PMID:21969517; http://dx.doi.org/10.1200/JCO.2011.36.5742
135. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007; 25:319-25; PMID:17235047; http://dx.doi.org/10.1200/JCO.2006.07.8824
136. Mantoni TS, Schendel RR, Rödel F, Niedobitek G, Al-Assar O, Masamune A, et al. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther 2008; 7:1806-15; PMID:18787407; http://dx.doi.org/10.4161/cbt.7.11.6846
137. Volk LD, Flister MJ, Chihade D, Desai N, Trieu V, Ran S. Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia 2011; 13:327-38; PMID:21472137
138. Robert N, Krekow L, Stokoe C, Clawson A, Iglesias J, O'Shaughnessy J. Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nabpaclitaxel is safe in women with early-stage breast cancer: a pilot study. Breast Cancer Res Treat 2011; 125:115-20; PMID:20945091; http://dx.doi.org/10. 1007/s10549-010-1187-2
139. Rahman M, Chan AP, Tai IT. A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo. PLoS One 2011; 6:e26390; PMID:22069448; http://dx.doi.org/10.1371/journal.pone.0026390
140. Tavor S, Eisenbach M, Jacob-Hirsch J, Golan T, Petit I, Benzion K, et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 2008; 22:2151-5158; PMID:18769446; http://dx.doi.org/10.1038/leu.2008.238
141. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 2011; 71:5522-34; PMID:21742774; http://dx.doi.org/10.1158/0008-5472. CAN-10-3143
142. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003; 100:13513-8; PMID:14595012; http://dx.doi.org/10.1073/pnas.2235846100
143. Yang L, Jackson E, Woerner BM, Perry A, Piwnica-Worms D, Rubin JB. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res 2007; 67:651-8; PMID:17234775; http://dx.doi.org/10.1158/0008- 5472.CAN-06-2762
144. Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 2011; 129:225-32; PMID:20830712; http://dx.doi.org/10. 1002/ijc.25665
145. Wu X, Lee VC, Chevalier E, Hwang ST. Chemokine receptors as targets for cancer therapy. Curr Pharm Des 2009; 15:742-57; PMID:19275640; http://dx.doi.org/10.2174/138161209787582165
146. Greco SJ, Patel SA, Bryan M, Pliner LF, Banerjee D, Rameshwar P. AMD3100-mediated production of interleukin-1 from mesenchymal stem cells is key to chemosensitivity of breast cancer cells. Am J Cancer Res 2011; 1:701-15; PMID:22016821
147. Neurath MF, Finotto S. IL-6 signaling in auto-immunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011; 22:83-9; PMID:21377916; http://dx.doi.org/10.1016/j.cytogfr.2011.02.003
148. Drygin D, Ho CB, Omori M, Bliesath J, Proffitt C, Rice R, et al. Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochem Biophys Res Commun 2011; 415:163-7; PMID:22027148; http://dx.doi.org/10.1016/j. bbrc.2011.10.046
149. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 17:6083-96; PMID:21795409; http://dx.doi.org/10.1158/1078-0432.CCR-11- 0945
150. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51:3602-9; PMID:1711413
151. Takeda I, Maruya S, Shirasaki T, Mizukami H, Takahata T, Myers JN, et al. Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci 2007; 98:890-9; PMID:17428261; http://dx.doi.org/10. 1111/j.1349-7006.2007.00471.x
152. Denoyelle C, Albanese P, Uzan G, Hong L, Vannier JP, Soria J, et al. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMGCoA reductase, on aggressive human breast cancer cells. Cell Signal 2003; 15:327-38; PMID:12531431; http://dx.doi.org/10.1016/S0898-6568(02)00124-9
153. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004; 104:1825-32; PMID:15161667; http://dx.doi.org/10.1182/blood-2003-12-4218
154. Kinbara K, Goldfinger LE, Hansen M, Chou FL, Ginsberg MH. Ras GTPases: integrins' friends or foes? Nat Rev Mol Cell Biol 2003; 4:767-76; PMID:14570053
155. Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 2009; 114:619-29; PMID:19443661; http://dx.doi.org/10.1182/blood-2009-01-199281
156. Kidera Y, Tsubaki M, Yamazoe Y, Shoji K, Nakamura H, Ogaki M, et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiledcoil-containing protein kinase pathway. J Exp Clin Cancer Res 2010; 29:127; PMID:20843370; http://dx.doi.org/10.1186/1756-9966-29-127
157. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8:97-106; PMID:21151206; http://dx.doi.org/10.1038/nrclinonc.2010.196
158. Bisht S, Brossart P, Maitra A, Feldmann G. Agents targeting the Hedgehog pathway for pancreatic cancer treatment. Curr Opin Investig Drugs 2010; 11:1387-98; PMID:21154121
159. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361:1164-72; PMID:19726763; http://dx.doi.org/10.1056/NEJMoa0905360
160. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173-8; PMID:19726761; http://dx.doi.org/10.1056/NEJMoa0902903
161. Thapa RJ, Basagoudanavar SH, Nogusa S, Irrinki K, Mallilankaraman K, Slifker MJ, et al. NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis. Mol Cell Biol 2011; 31:2934-46; PMID:21576359; http://dx.doi.org/10.1128/MCB.05445-11